MDxHealth hits testing milestone with prostate cancer epigenetic Dx

ConfirmMDx detects an epigenetic field effect.--Courtesy of MDxHealth

MDxHealth ($MDXH) is celebrating positive results from recent studies of its prostate cancer molecular diagnostic test. The Belgium-based company says its ConfirmMDx test reaffirmed researchers' hopes that their test could produce a more personalized--and accurate--prostate cancer diagnosis when an initial biopsy comes back negative. About 650,000 American men each year experience prostate biopsies that come back negative, even though an estimated 25% of them may still have cancer, MDxHealth estimates. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.